| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 02/09/2005 | CN1578786A Linear basic compounds having nk-2 antagonist activity and formulations thereof |
| 02/09/2005 | CN1578781A 1, 8 naphthyridine derivatives and their use to treat diabetes and related disorders |
| 02/09/2005 | CN1578780A 1, 6-naphthyridine derivatives as antidiabetics and pharmaceutical compositions containing them |
| 02/09/2005 | CN1578779A Small organic molecule regulators of cell proliferation |
| 02/09/2005 | CN1578778A Tetrahydropyran derivatives and their use as therapeutic agents |
| 02/09/2005 | CN1578773A Methods and compositions of novel triazine compounds |
| 02/09/2005 | CN1578772A Crystalline sodium salt of telmisartan and the use of the same as an angiotensin antagonist |
| 02/09/2005 | CN1578678A Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use |
| 02/09/2005 | CN1578674A Cyclooxygenase-2 inhibitor/histone deacetylase inhibitor combination |
| 02/09/2005 | CN1578672A Rsv基因表达疫苗 Rsv gene expression vaccine |
| 02/09/2005 | CN1578667A Anticancer compositions |
| 02/09/2005 | CN1578665A Type 4 phosphodiesterase inhibitors and uses thereof |
| 02/09/2005 | CN1578663A Inhibitors of histone deacetylase |
| 02/09/2005 | CN1578662A Pyridine derivatives as nmda-receptor subtype blockers |
| 02/09/2005 | CN1578661A Naphthyridine derivatives, their preparation and their use as phosphodiesterase isoenzyme 4 (pde4) inhibitors |
| 02/09/2005 | CN1578659A Modulators of peroxisome proliferator activated receptors (ppar) |
| 02/09/2005 | CN1578650A Compositions for the treatment of infectious diseases |
| 02/09/2005 | CN1578626A Multivesicular emulsion topical delivery systems |
| 02/09/2005 | CN1576275A Substituted bicyclic derivatives for the treatment of abnormal cell growth |
| 02/09/2005 | CN1575816A Compounds for the treatment of female sexual dysfunction |
| 02/09/2005 | CN1575802A Composition for suppressing blood sugar ascending |
| 02/09/2005 | CN1575797A New use of medicine containing escin and its salt |
| 02/09/2005 | CN1188415C Pyrazolopyrimidinones which inhibit type 5 cyclic guanosine 3', 5'-monophosphate phosphodiesterase (cGMP PDE5)for treatment of sexual dysfunction |
| 02/09/2005 | CN1188413C Compound for treatment of pain |
| 02/09/2005 | CN1188412C Process for preparing crystalline form 1 of cabergoline |
| 02/09/2005 | CN1188410C Nonsteroid IL-5 inhibitor, its preparation method and medical composition containing the same inhibitor |
| 02/09/2005 | CN1188407C Imidazole derivatives with farnesyl transferase to inhibite activity and preparing method thereof |
| 02/09/2005 | CN1188405C New Morpholinobenzamide salts |
| 02/09/2005 | CN1188404C Cyclic compound |
| 02/09/2005 | CN1188403C Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
| 02/09/2005 | CN1188402C Piperazinone derivs. and their uses |
| 02/09/2005 | CN1188394C N-substituted-N'-substituted urea derivative and medicinal compositions containing the same |
| 02/09/2005 | CN1188389C Benzamide derivatives for the treatment of diseases caused by cytokines |
| 02/09/2005 | CN1188164C Compositions and method for regulating phagocytosis and ICAM-1 expression |
| 02/09/2005 | CN1188140C Reduction of oxidative stress factors |
| 02/09/2005 | CN1188137C Use of erythrogenin and molecule with active EPO receptor ability or analog EPO activation in pharmacy |
| 02/09/2005 | CN1188134C Preparation having increased in vivo tolerability |
| 02/09/2005 | CN1188121C Therapeutic substituted guanidines |
| 02/09/2005 | CN1188105C polymer used in formula of cosmetics |
| 02/08/2005 | US6852863 Osteoporosis; immunosuppressants; wound healing agent |
| 02/08/2005 | US6852839 Fhm, a novel member of the TNF ligand supergene family |
| 02/08/2005 | US6852835 DNA molecules and polypeptides of Pseudomonas syringae Hrp pathogenicity island and their uses |
| 02/08/2005 | US6852755 This invention pertains to nitrogen mustard compounds (Formula (II)) and prodrugs therefor (Formula (I)), methods for their preparation, pharmaceutical compositions comprising such compounds, and the use of such compounds and |
| 02/08/2005 | US6852753 Treating hyperlipidemic condition, gallstones |
| 02/08/2005 | US6852747 Resorcinol derivatives |
| 02/08/2005 | US6852744 Pyrrolidine derivatives and their use as chymase inhibitor |
| 02/08/2005 | US6852743 Preventives for the recurrence of cerebrovascular failure and agents for ameliorating troubles following cerebrovascular failure and inhibiting progress thereof |
| 02/08/2005 | US6852740 Treating p38 kinase mediated disorders. Compounds of particular interest are defined by Formula I Mitogen-activated protein kinases (MAP) is a family of proline- directed serine/threonine kinases that activate their |
| 02/08/2005 | US6852738 Potent ligands for PPAR gamma and generally have antagonist or partial agonist activity. The compoundsare for treatment, control or prevention of obesity, non-insulin dependent diabetes mellitus (NIDDM), hyperglycemia, dyslipidemia, |
| 02/08/2005 | US6852735 Novel siastatin B derivative having a potent inhibitory activity against a glycosidase, are now synthesized by new processes. The a potent enzyme inhibitory activity to a glycosidase, which is particularly N- |
| 02/08/2005 | US6852734 Indole wherein A is an oxygen atom or a nitrogen atom which nitrogen atom is optionally substituted with an alkyl group, and (i) R1 and R2 each stand for a hydrogen atom or an alkyl group, independently, or (ii) R1 and R2 as taken together form |
| 02/08/2005 | US6852732 A tetrahydropyridino or piperidino heterocyclic derivative represented by the formula (I): has a high affinity for CRF receptors and is effective against diseases in which CRF is considered to be involved. (Corticotropin releasing factor |
| 02/08/2005 | US6852730 Substituted fused pyrazolecarboxylic acid arylamides and related compounds |
| 02/08/2005 | US6852727 Inhibitors of Janus protein tyrosine kinases (Jak), and as such are useful as immunosuppressants, and in the treatment of diseases including asthma, allergies, autoimmune diseases. |
| 02/08/2005 | US6852726 Such as 1-(4,5-dihydro-1H-imidazol-2-ylmethyl)-3-methanesulfonyl-2-methyl-1H-indole for preventing/treating disorders modulated by alpha-1A/L adrenoceptors such as urinary incontinence and sexual disorders |
| 02/08/2005 | US6852725 Imidazolyl derivatives |
| 02/08/2005 | US6852721 Compounds capable of activating nicotinic cholinergic receptors; N-aryl diazabicyclic compounds such as (1S,4S)-2-(5-(3-methoxyphenoxy)-3-pyridyl)-2,5-diazabicyclo(2. 2.1)-heptane; treating central nervous system disorders |
| 02/08/2005 | US6852720 Thiazol-2-yl-imine compounds as PDE-7 inhibitors |
| 02/08/2005 | US6852718 Selective 5-HT2A antagonists useful in treatment or prevention of CNS conditions |
| 02/08/2005 | US6852717 Inhibit the release of inflammatory cytokines such as interleukin-1 and tumor necrosis factor; for use in therapy of diseases and pathological conditions involving inflammation such as chronic inflammatory disease |
| 02/08/2005 | US6852716 Central nervous system disorders; psychological disorders |
| 02/08/2005 | US6852714 (Benzodioxan, benzofuran or benzopyran) derivatives having fundic relaxation properties |
| 02/08/2005 | US6852712 Controlling cell differentiation; antiinflammatory agents |
| 02/08/2005 | US6852707 Using xylobiose or xylooligosaccharide containing xylobiose as a main ingredient in place of lactulose, there is provided a blood ammonia lowering agent, a therapeutic agent of hyperammonemia or a therapeutic agent of hepatic |
| 02/08/2005 | US6852693 Compositions and methods for promoting lipid mobilization in humans |
| 02/08/2005 | US6852520 DSP-2 dual-specificity phosphatase |
| 02/08/2005 | US6852518 Glycosyl sulfotransferases GST-4α, GST-4β, and GST-6 |
| 02/08/2005 | US6852320 T cell inhibitory receptor compositions and uses thereof |
| 02/08/2005 | CA2322900C 2-(hetero)aryl-substituted purin-6-ones as phosphodiesterase inhibitors |
| 02/08/2005 | CA2180103C Gene encoding adseverin |
| 02/08/2005 | CA2164050C Cosmetic compositions containing betulinic acid |
| 02/08/2005 | CA2097208C The sulphate salt of a substituted triazole, pharmaceutical compositions thereof, and their use in therapy |
| 02/08/2005 | CA2096525C Retroviral protease inhibitors |
| 02/08/2005 | CA2096409C Retroviral protease inhibitors |
| 02/08/2005 | CA2096408C Retroviral protease inhibitors |
| 02/03/2005 | WO2005010189A1 OLIGONUCLEOTIDE INHIBITING THE EXPRESSION OF StAR-BINDING PROTEIN (SBP) GENE AND METHOD THEREFOR |
| 02/03/2005 | WO2005009956A1 (2s,4s)-4-fluoro-1-[4-fluoro-beta-(4-fluorophenyl)-l-phenylalanyl]-2-pyrrolidinecarbonitrile p-toluenesulfonic acid salt and anhydrous crystalline forms thereof |
| 02/03/2005 | WO2005009947A2 Aryl heteroaromatic products, compositions comprising the same and use thereof |
| 02/03/2005 | WO2005009942A1 Optically active substituted phenylpropionic acid derivative |
| 02/03/2005 | WO2005009480A2 Implants containing codrugs |
| 02/03/2005 | WO2005009475A1 Medicinal preparation containing component originating in bacteruim belonging to the genus clostridium |
| 02/03/2005 | WO2005009469A1 Novel drug for regulating blood sugar and method of screening the same |
| 02/03/2005 | WO2005009468A1 Remedy for cartilage-related diseases |
| 02/03/2005 | WO2005009450A2 Use of botulinum toxin for producing drug for preventing or treating final phase of lung troubles |
| 02/03/2005 | WO2005009423A1 Necrosis avid tracer agent |
| 02/03/2005 | WO2004009083A8 Antitumor compound and therapeutic uses thereof |
| 02/03/2005 | WO2003064606A3 Human monoclonal antibodies to prostate specific membrane antigen (psma) |
| 02/03/2005 | WO2003062390A3 Compositions and methods for the modulation of sphingolipid metabolism and/or signaling |
| 02/03/2005 | WO2002096360A3 Single amino acid based compounds for counteracting effects of reactive oxygen species and free radicals |
| 02/03/2005 | US20050027125 Intensifiers of adenosine receptors for cardiac arrhythmia |
| 02/03/2005 | US20050027121 Heterocyclic carboxy amines such as (2R)-1-[3,5-Bis(trifluoromethyl)benzoyl]-4-[4-((3S)-3-ethylmorpholino)-2-butynyl]-2-[(1H-indol-3-yl)methyl]piperazine, used as substance P and neurokinin antagonist for prophylaxis of diseases |
| 02/03/2005 | US20050027114 Methods and materials relating to cd84-like polypeptides and polynucleotides |
| 02/03/2005 | US20050027013 LTA4 hydrolase inhibitors |
| 02/03/2005 | US20050027009 New derivatives of N-(iminomethyl)amines, their preparation, their use as medicaments and the pharmaceutical compositions containing them |
| 02/03/2005 | US20050026997 Baccatin III analog containing a small peptide moiety; can be conjugated to cell binding agents; improved potency |
| 02/03/2005 | US20050026996 A taxane such as paclitaxel or docetaxel joined by a hydrolyzable bond to one or more oligomers having a polyethylene glycol moiety; amphiphilic drug conjugate with improved water solubility without drastic increase in molecular weight |
| 02/03/2005 | US20050026994 Treating proliferative diseases such as tumors; 4-[4-(2-Benzyloxycarbonylamino-3-methyl-butyrylamino)-3-hydroxy-2-(4-methoxy-benzylamino)-5-phenyl-pentanoylamino]4-(2-hydroxy-4-methoxy-benzylcarbamoyl)-butyric acid methyl ester for example |
| 02/03/2005 | US20050026990 N-[(3S)-1-hydroxy-2-oxopyrrolidinyl]-N-methyl-4'-(trifluoromethyl)[1,1'-biphenyl]-4-sulfonamide or derivatives to treat Respiratory system disorders; arthritis, and bone disorders |
| 02/03/2005 | US20050026988 Cyclopenta'b! indole derivatives as spla inhibitors |
| 02/03/2005 | US20050026986 Use of central cannabinoid receptor antagonists for the preparation of drugs |